Gland Pharma Limited — Investor Meet, 27-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Gland Pharma posted consolidated Q4 revenue of INR 1,424.9 Cr with a 24% EBITDA margin, up 100bps YoY. Base business revenue fell 12% YoY to INR 103.32 Cr but saw margin improvement to 38% on better mix and cost control. Net profit rose 3% QoQ to INR 186.5 Cr. US volumes grew 9%, supported by 31 product launches. Management expects mid-teen consolidated revenue growth driven by US, new launches, tech transfers, dry powder, and biologics capacities expanding to 140 million units by CY26. Cenexi posted €43 million revenue with 79% gross margin and aims to breakeven by Q3 FY26, backed by €60 million investments and capacity additions. Focus areas include geographic expansion, portfolio diversification, supply chain enhancement, and inorganic growth. Net cash (ex-Cenexi debt) stands at INR 2,287 Cr with INR 915 Cr operating cash flow. Sentiment is cautiously optimistic, supported by pipeline and operational progress.